Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Principles (Tables)

Summary of Significant Accounting Principles (Tables)

9 Months Ended

Sep. 30, 2020

Summary of Calculation of Basic Net Income Per Share

The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2020		2019			2020			2019
Basic and Diluted Income (Loss) Per Share
Net income (loss)	$	11,685	$	(10,315	)	$	(59,058	)	$	(25,232	)
Weighted average common shares outstanding, basic		18,374,604		9,350,709			15,366,861			9,350,709
Dilutive effect of equity awards, based on the treasury stock method		393,772		—			—			—
Weighted average common shares outstanding, diluted		18,768,376		9,350,709			15,366,861			9,350,709

Schedule of Anti-Dilutive Securities

The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as they would be anti-dilutive:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Options and restricted stock units outstanding		2,098,316		—		1,694,889		—
Warrants		15,107,100		—		15,199,605		—